Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients

Eric J Heyer, Joanna L Mergeche, Samuel S Bruce, E Sander Connolly, Eric J Heyer, Joanna L Mergeche, Samuel S Bruce, E Sander Connolly

Abstract

Objective: Type 2 diabetic patients have a high incidence of cerebrovascular disease, elevated inflammation, and high risk of developing cognitive dysfunction following carotid endarterectomy (CEA). To elucidate the relationship between inflammation and the risk of cognitive dysfunction in type 2 diabetic patients, we aim to determine whether elevated levels of systemic inflammatory markers are associated with cognitive dysfunction 1 day after CEA.

Research design and methods: One hundred fifteen type 2 diabetic CEA patients and 156 reference surgical patients were recruited with written informed consent in this single-center cohort study. All patients were evaluated with an extensive battery of neuropsychometric tests. Preoperative monocyte counts, HbA1c, C-reactive protein (CRP), intercellular adhesion molecule 1, and matrix metalloproteinase 9 activity levels were obtained.

Results: In a multivariate logistic regression model constructed to identify predictors of cognitive dysfunction in type 2 diabetic CEA patients, each unit of monocyte counts (odds ratio [OR] 1.76 [95% CI 1.17-2.93]; P=0.005) and CRP (OR 1.17 [1.10-1.29]; P<0.001) was significantly associated with higher odds of developing cognitive dysfunction 1 day after CEA in type 2 diabetic patients.

Conclusions: Type 2 diabetic patients with elevated levels of preoperative systemic inflammatory markers exhibit more cognitive dysfunction 1 day after CEA. These observations have implications for the preoperative medical management of this high-risk group of surgical patients undergoing carotid revascularization with CEA.

Trial registration: ClinicalTrials.gov NCT00597883.

References

    1. Kissela BM, Khoury J, Kleindorfer D, et al. Epidemiology of ischemic stroke in patients with diabetes: the greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005;28:355–359
    1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105–111
    1. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994;25:1157–1164
    1. Rothwell PM. Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. Cerebrovasc Dis 2005;20(Suppl. 1):24–34
    1. Heyer EJ, Adams DC, Solomon RA, et al. Neuropsychometric changes in patients after carotid endarterectomy. Stroke 1998;29:1110–1115
    1. Heyer EJ, Sharma R, Rampersad A, et al. A controlled prospective study of neuropsychological dysfunction following carotid endarterectomy. Arch Neurol 2002;59:217–222
    1. Connolly ES, Jr., Winfree CJ, Rampersad A, et al. Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotid endarterectomy. Neurosurgery 2001;49:1076–1082; discussion 1082–1083
    1. Aleksic M, Heckenkamp J, Reichert V, Gawenda M, Brunkwall J. S-100B release during carotid endarterectomy under local anesthesia. Ann Vasc Surg 2007;21:571–575
    1. Heyer EJ, Mergeche JL, Bruce SS, et al. Statins reduce neurologic injury in asymptomatic carotid endarterectomy patients. Stroke 2013;44:1150–1152
    1. Mocco J, Wilson DA, Komotar RJ, et al. Predictors of neurocognitive decline after carotid endarterectomy. Neurosurgery 2006;58:844–850; discussion 844–850
    1. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation 1978;57:133–136
    1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419–S420
    1. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003;41:1071–1077
    1. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001;15:203–210
    1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979
    1. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L; FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139–1147
    1. Ferreirós ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999;100:1958–1963
    1. Biasucci LM, Santamaria M, Liuzzo G. [Inflammation, atherosclerosis and acute coronary syndromes]. Minerva Cardioangiol 2002;50:475–486 [In Italian]
    1. Leinonen ES, Hiukka A, Hurt-Camejo E, et al. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. J Intern Med 2004;256:119–127
    1. Winberg JO, Kolset SO, Berg E, Uhlin-Hansen L. Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J Mol Biol 2000;304:669–680
    1. Helmersson-Karlqvist J, Akerfeldt T, Gunningberg L, Swenne CL, Larsson A. Serum MMP-9 and TIMP-1 concentrations and MMP-9 activity during surgery-induced inflammation in humans. Clin Chem Lab Med 2012;50:1115–1119
    1. Xu X, Jackson PL, Tanner S, et al. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One 2011;6:e15781.
    1. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006;18:145–157
    1. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 2009;276:13–26
    1. Mocco J, Choudhri TF, Mack WJ, et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 2001;48:718–721; discussion 721–722
    1. Mocco J, Wilson DA, Ducruet AF, et al. Elevations in preoperative monocyte count predispose to acute neurocognitive decline after carotid endarterectomy for asymptomatic carotid artery stenosis. Stroke 2006;37:240–242
    1. Gaudet JG, Yocum GT, Lee SS, et al. MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery. J Clin Neurosci 2010;17:436–440
    1. Heyer EJ, DeLaPaz R, Halazun HJ, et al. Neuropsychological dysfunction in the absence of structural evidence for cerebral ischemia after uncomplicated carotid endarterectomy. Neurosurgery 2006;58:474–480; discussion 474–480
    1. Gigante PR, Kotchetkov IS, Kellner CP, et al. Polymorphisms in complement component 3 (C3F) and complement factor H (Y402H) increase the risk of postoperative neurocognitive dysfunction following carotid endarterectomy. J Neurol Neurosurg Psychiatry 2011;82:247–253
    1. Moller JT, Cluitmans P, Rasmussen LS, et al. International Study of Post-Operative Cognitive Dysfunction Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. Lancet 1998;351:857–861
    1. Rasmussen LS. Defining postoperative cognitive dysfunction. Eur J Anaesthesiol 1998;15:761–764
    1. Heyer EJ, Wilson DA, Sahlein DH, et al. APOE-epsilon4 predisposes to cognitive dysfunction following uncomplicated carotid endarterectomy. Neurology 2005;65:1759–1763
    1. Dandona P, Chaudhuri A, Mohanty P, Ghanim H. Anti-inflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007;10:511–517
    1. Gorelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci 2010;1207:155–162
    1. Steinmetz J, Christensen KB, Lund T, Lohse N, Rasmussen LS, ISPOCD Group Long-term consequences of postoperative cognitive dysfunction. Anesthesiology 2009;110:548–555

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe